HRT After a Blood Clot: What Options Remain

Does a past blood clot rule out HRT completely?

A past blood clot rarely closes the door on treating menopause symptoms, though it reshapes the options. Current guidance from the North American Menopause Society frames candidacy individually 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Individualized candidacy for menopausal hormone therapy, the lower clot risk of transdermal versus oral estrogen, and the role of personal clot history in the risk-benefit decision.. In the Women's Health Initiative, oral estrogen plus progestin roughly doubled the rate of blood clots — from about 16 to 34 cases per 10,000 women each year 2Ref 2Rossouw JE, Anderson GL, Prentice RL, et al. / Writing Group for the Women's Health Initiative Investigators (2002).Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.The WHI randomized trial in which oral estrogen plus progestin roughly doubled venous thromboembolism risk, establishing that oral estrogen raises clot risk. — so pills are usually avoided after a clot. Hormone therapy is generally reserved for women under 60 or within 10 years of menopause 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Individualized candidacy for menopausal hormone therapy, the lower clot risk of transdermal versus oral estrogen, and the role of personal clot history in the risk-benefit decision., and a clot history shifts it further. Even so, the absolute risk for any one person stays well under 1 in 100 a year 2Ref 2Rossouw JE, Anderson GL, Prentice RL, et al. / Writing Group for the Women's Health Initiative Investigators (2002).Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.The WHI randomized trial in which oral estrogen plus progestin roughly doubled venous thromboembolism risk, establishing that oral estrogen raises clot risk., and many women with a remote, well-explained clot can still consider a lower-risk route or a non-hormonal plan. This is a shared hormone therapy decision, not an automatic no.

Why is transdermal estrogen safer for clot risk?

Estrogen delivered through the skin bypasses the first pass through the liver, where oral estrogen drives production of the clotting factors that raise thrombosis risk. Because of that, transdermal estradiol has not been linked to a higher clot risk in the way oral forms have 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Individualized candidacy for menopausal hormone therapy, the lower clot risk of transdermal versus oral estrogen, and the role of personal clot history in the risk-benefit decision.. The NICE menopause guideline recommends considering transdermal rather than oral estrogen for women who are at increased risk of a clot 3Ref 3National Institute for Health and Care Excellence (2026).Menopause: identification and management (NG23).NICE menopause guidance recommending transdermal rather than oral estrogen for women at increased risk of venous thromboembolism.. Common lower-risk options include:

• Estrogen patches, gels, or sprays for hot flashes and night sweats 4Ref 4MedlinePlus (National Library of Medicine) (2026).Hormone Replacement Therapy.Patient-facing overview of hormone therapy forms, including transdermal patches, gels, and sprays for vasomotor symptoms.
• Local vaginal estrogen, which has minimal absorption and negligible clot effect
• Non-hormonal medicines and lifestyle steps when hormones are best avoided

Most of these keep symptom relief on the table while lowering the specific risk that a clot history raises.

What do clot type and cause change?

The reason a clot happened matters as much as the fact that it happened. A provoked clot — one triggered by surgery, a long-leg cast, pregnancy, or the estrogen in birth control pills — carries a different outlook than an unprovoked clot that arrived without explanation. An inherited clotting tendency such as factor V Leiden, the most common thrombophilia, raises baseline risk and usually prompts closer review. Whether you are still on a blood thinner also shapes the plan. Situations like a DVT after a long flight sit differently from a clot with no clear cause. According to menopause guidance, these details, not a single label, drive whether transdermal hormones are reasonable 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Individualized candidacy for menopausal hormone therapy, the lower clot risk of transdermal versus oral estrogen, and the role of personal clot history in the risk-benefit decision.3Ref 3National Institute for Health and Care Excellence (2026).Menopause: identification and management (NG23).NICE menopause guidance recommending transdermal rather than oral estrogen for women at increased risk of venous thromboembolism..

Does age or early menopause change the decision?

Life stage shifts the balance between a clot survivor's risks and the benefits of hormones. In premature ovarian insufficiency or early menopause before about age 40, guidelines generally support replacing hormones until around the average age of natural menopause for bone and heart protection, which can tip the balance toward treatment even with a clot history — usually through a transdermal route 5Ref 5Panay N, et al. (ESHRE/ASRM/CREWHIRL/IMS) (2025).Evidence-based guideline: Premature Ovarian Insufficiency.Guideline support for hormone therapy until the average age of menopause in premature ovarian insufficiency for bone and cardiovascular protection.. Across the perimenopausal transition in the 40s and early 50s, symptoms such as night sweats and clot risk both evolve, so a plan set at one stage often deserves a fresh look years later. Age and time since menopause change the math in both directions.

When a clinician and hematologist can help

A clinician who knows your full clot history is best placed to map the safest path. A gynecologist or menopause clinician can weigh symptoms, the type and cause of the clot, and your current risk, and often co-manages with a hematologist when a clotting disorder is involved or you remain on anticoagulation. Together they can compare a transdermal route, local options, and non-hormonal choices, and set a monitoring plan. Gale can help you gather your clot history and questions before that visit.